1. ¹Division of Urology, University of Buenos Aires, Buenos Aires, Argentina
2. ²Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA
3. ³Welborn Clinic, Evansville, IN, USA
4. ⁴Clinical Development, GlaxoSmithKline, Research Triangle Park, NC, USA
5. ⁵Biostatistics and Programming, GlaxoSmithKline, Research Triangle Park, NC, USA
6. ⁶Department of Urology, Università Vita-Salute San Raffaele, Milan, Italy

Correspondence: Dr E Becher, Division of Urology, University of Buenos Aires, Ave Cordoba 2424, Buenos Aires C1120AAT, Argentina. E-mail: ebecher@cdu.com.ar

Received 7 April 2009; Revised 14 July 2009; Accepted 21 July 2009; Published online 1 September 2009.

Abstract

This article reports the results of a post hoc analysis of the multicenter, randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) study, which aimed to investigate the effects of dutasteride (0.5 mg), tamsulosin (0.4 mg), and their combination on storage and voiding symptoms in 4844 men aged 50 years with moderate-to-severe lower urinary tract symptoms (International Prostate Symptom Score 12), prostate volume (PV) 30 cm³ and PSA 1.5–10 ng ml^-1. After 24 months, combination treatment achieved significantly greater mean reductions in both voiding and storage symptoms than either monotherapy, in each of the three baseline PV tertiles (30 to <42, 42 to <58, 58 cm³). Dutasteride was as effective as tamsulosin for control of storage symptoms, but provided significantly greater relief of voiding symptoms than tamsulosin.